ECX.DE

Epigenomics AG [ECX.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ECX.DE Stock Summary

In the News

ECX.DE Financial details

Company Rating
-
Market Cap
0
Income
-16.29M
Revenue
448K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
36
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-21.74
Forward P/E
-
PEG
-0.62
P/S
-
P/B
8.69
P/C
-
P/FCF
-
Quick Ratio
3.62
Current Ratio
3.88
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.9
EPS next Y
-
EPS next Q
-
EPS this Y
240.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
26.88%
Revenue last 5Y
-20.56%
Revenue Q/Q
-47.76%
EPS Q/Q
-52.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-29%
ROE
-34%
ROC
-0.37%
Gross Margin
76%
Oper. Margin
-1412%
Profit Margin
-1442%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.55-6.2
52W High
-88.33%
52W Low
-30%
RSI
-
Rel Volume
9.01
Avg Volume
562
Volume
5.06K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-11.17%
-
-
-
-
Beta
-
-
-
Volatility
0.04%, 0.04%
Prev Close
0%
Price
0.7
Change
34.62%

Something similar

Top by Market Cap
BRK-B
TSLA
ABEC.DE
VFINX
LLY
Same Sector
BLISSGVS.NS
001360.KS
OFIX
PHI1.DE
BIOS.ST
Check Those
PRC.PA
WELENT.NS
8070.SR
002517.SZ
AGCZ
Similar Market Cap
EFV
RNMC
0NZ1.L
600563.SS
2025.TW

Company Profile

Healthcare Medical - Diagnostics & Research

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.